Blog
RSS FeedPosted by Michael Wonder on 11 Aug 2020
Alkindi approved in Australia
10 August 2020 - Diurnal Group announces that Alkindi (hydrocortisone granules in capsules for opening) has been approved by the ...
Posted by Michael Wonder on 10 Aug 2020
SMC - August 2020 decisions
10 August 2020 - The Scottish Medicines Consortium has today published advice accepting neratinib (Nerlynx) for the treatment of breast ...
Posted by Michael Wonder on 08 Aug 2020
U.S. Food and Drug Administration approves Lampit (nifurtimox) for the treatment of Chagas disease in children
7 August 2020 - Only Chagas disease treatment approved in U.S. for use in children from birth to less than 18 ...
Posted by Michael Wonder on 08 Aug 2020
FDA approves new opioid for intravenous use in hospitals, other controlled clinical settings
7 August 2020 - Today, the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management ...
Posted by Michael Wonder on 07 Aug 2020
Rheumatoid arthritis drug Rinvoq gets insurance benefit
7 August 2020 - AbbVie Korea’s rheumatoid arthritis treatment Rinvoq (upadacitinib) has obtained the national health insurance benefit. ...
Posted by Michael Wonder on 07 Aug 2020
FDA approves first liquid biopsy next generation sequencing companion diagnostic test
7 August 2020 - Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses ...
Posted by Michael Wonder on 07 Aug 2020
FDA approves oral treatment for spinal muscular atrophy
7 August 2020 - The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age ...
Posted by Michael Wonder on 07 Aug 2020
Novartis receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
6 August 2020 - EC approves Xolair (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first ...
Posted by Michael Wonder on 07 Aug 2020
Catalyst Pharmaceuticals’ Firdapse (amifampridine phosphate) receives marketing approval in Canada for patients with LEMS
6 August 2020 - Catalyst Pharmaceuticals today announced that Canada’s national health care regulatory agency, Health Canada, has approved the ...
Posted by Michael Wonder on 06 Aug 2020
NICE supports use of new medicine for patients with malignant disease
5 August 2020 - Treosulphan is used as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation. ...
Posted by Michael Wonder on 06 Aug 2020
Darolutamide in prostate cancer: indication of considerable added benefit
3 August 2020 - Advantages in overall survival, symptoms and health-related quality of life. ...
Posted by Michael Wonder on 06 Aug 2020
FDA approves GSK’s Blenrep (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma
6 August 2020 - Blenrep is the fifth major medicine approval for GSK in 2020. ...
Posted by Michael Wonder on 06 Aug 2020
Cimzia is the first and only biologic approved in Europe with the option for a reduced maintenance dose for patients across the full axial spondyloarthritis spectrum
5 August 2020 - European label extended to include a dose reduction option for the treatment of adult patients with axial ...
Posted by Michael Wonder on 05 Aug 2020
NICE publishes draft guidance on the use of a topical gel by patients with a rare cancer
5 August 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using chlormethine gel ...
Posted by Michael Wonder on 05 Aug 2020
Roche announces FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients
5 August 2020 - FDA granted de novo class II for cobas EBV test following the agency’s breakthrough device designation. ...